- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
April 17th, 2007
Representatives from Merck will make a special presentation to researchers and scientists in universities and companies at the Nanotech 2007 conference on May 23, 2007 at the Santa Clara Convention Center in California.
Merck recently acquired Sirna Therapeutics, a leader in efforts to create RNAi-based therapeutics that could significantly alter the treatment of disease. RNAi-based therapeutics selectively catalyze the destruction of the RNA transcribed from an individual gene enabling an novel approach to discovering drugs with the potential to produce highly specific, potent, and long-lasting effects.
|Related News Press|
Sniffing out cancer with improved 'electronic nose' sensors October 2nd, 2015
Hopes of improved brain implants October 1st, 2015
New Nanomaterials Taking Research to Mexico, Possibly into Space September 29th, 2015
Production of High Temperature Ceramics with Modified Properties in Iran October 2nd, 2015
ISO Approves 2 Int'l Nanotechnology-Related Standards Proposed by Iran October 2nd, 2015
Arrowhead Nominates ARC-HIF2 As First RNAi Therapeutic Candidate Using Extrahepatic DPC(TM) Delivery System: Data to be presented September 27 at the European Cancer Conference 2015 in Vienna September 11th, 2015